Tiotropium in Children and Adolescents With Asthma.
Asthma is a major cause of morbidity in children, despite the availability of various treatments. In adults, tiotropium-a long-acting muscarinic antagonist (LAMA)-as add-on therapy to an inhaled corticosteroid (ICS) with or without a long-acting β2-agonist provides clinical benefit with a safety profile similar to placebo. To review published evidence on the efficacy and safety of tiotropium as add-on LAMA therapy in children and adolescents with asthma that is uncontrolled despite use of an ICS with or without additional controller medication(s). We searched PubMed from inception until June 12, 2018, for randomized controlled trials (RCTs) involving children and adolescents aged 1 to 17 years treated with tiotropium Respimat® and reporting a primary outcome of any pulmonary function test and a secondary outcome of adverse events (AEs). Overall, 7 RCTs involving 1902 preschool children (aged 1-5 years; n = 102), school-age children (aged 6-11 years; n = 905), and adolescents (aged 12-17 years; n = 895) with moderate-to-severe asthma were included in the analysis. Once-daily tiotropium (5, 2.5, 1.25 μg) improved lung function parameters, including peak and trough forced expiratory volume in 1 second, versus placebo. Commonly reported AEs across treatment groups included asthma worsening or exacerbations, decreased peak expiratory flow rate, nasopharyngitis, viral respiratory tract infection, and respiratory tract infection. Once-daily tiotropium as add-on therapy is efficacious and safe in adolescents and children with moderate-to-severe asthma. These results support the expanded indication by regulatory authorities for add-on tiotropium in patients aged ≥6 years.